Daily Ards Research Analysis
Analyzed 15 papers and selected 3 impactful papers.
Summary
Analyzed 15 papers and selected 3 impactful articles.
Selected Articles
1. Microbial metabolite oxindole curbs acute lung injury by suppressing CXCL13.
Human plasma metabolomics revealed dysregulated tryptophan metabolism in ARDS, and mouse dietary experiments showed that high tryptophan intake ameliorated ALI in a microbiota-dependent manner. Mechanistically, the microbial metabolite oxindole curtailed lung injury by suppressing CXCL13, linking the gut–lung axis to chemokine-driven inflammation.
Impact: This integrative human–animal study identifies a gut-derived metabolite (oxindole) and a CXCL13 pathway as actionable drivers of lung injury, advancing mechanistic understanding and suggesting testable therapeutic strategies.
Clinical Implications: Findings motivate trials of diet/microbiome modulation and CXCL13-targeted approaches in ALI/ARDS, and support metabolic profiling to identify patients with dysregulated tryptophan pathways.
Key Findings
- Untargeted plasma metabolomics showed significant dysregulation of tryptophan metabolism in ARDS patients versus healthy controls.
- In murine ALI, high tryptophan intake reduced injury severity, while deficiency worsened it; protection depended on the gut microbiota.
- The microbial metabolite oxindole curtailed lung injury by suppressing CXCL13, implicating a gut–lung chemokine axis.
Methodological Strengths
- Integrative design combining human untargeted metabolomics with in vivo dietary and microbiota-dependent mouse experiments
- Microbiome profiling (16S rRNA gene sequencing) to link metabolic changes with taxa shifts
Limitations
- Translational gap: mechanistic findings require validation in interventional human studies
- Specific causative microbial taxa and dose–response relationships for oxindole are not fully delineated in the abstract
Future Directions: Evaluate oxindole/CXCL13-targeted interventions and dietary/microbiome modulation in early-phase clinical trials; refine patient stratification using tryptophan-metabolite signatures.
The gut-lung axis is involved in acute lung injury (ALI) and its fatal sequela, acute respiratory distress syndrome (ARDS), yet the molecular mechanisms governing this crosstalk remain poorly defined. Untargeted metabolomics of plasma revealed significant dysregulation of tryptophan metabolism in ARDS patients compared to healthy controls. Murine dietary interventions demonstrated that high tryptophan intake alleviated ALI severity, whereas deficiency exacerbated injury, with protection being gut microbiota dependent. 16S ribosomal RNA (16S rRNA) gene sequencing revealed marked depletion of a functionally central bacterium
2. Early lung ultrasound score combined with umbilical cord-blood procalcitonin improves 1-year prognostic stratification in preterm neonates with respiratory distress syndrome.
In a single-center prospective cohort of 290 very preterm infants with RDS, a standardized 12-zone LUS and cord-blood PCT obtained within 6 hours of birth predicted a 12-month composite morbidity/death. The combined model (AUC 0.87) outperformed each marker alone (LUS 0.76; PCT 0.78), with internal validation by bootstrap.
Impact: Demonstrates a practical, bedside, early risk stratification tool combining imaging and a biomarker to predict long-term outcomes, with strong discrimination and internal validation.
Clinical Implications: Early integration of LUS and cord-blood PCT can guide surveillance intensity, respiratory support planning, and early interventions in very preterm RDS while awaiting external validation.
Key Findings
- Among 290 preterm infants with RDS, 37.9% reached the 12-month composite endpoint.
- LUS alone AUC 0.76 and PCT alone AUC 0.78; combining LUS with log-transformed PCT improved AUC to 0.87 (0.83–0.92).
- Time-to-event associations evaluated by multivariable Cox regression; internal validation performed with bootstrap optimism correction.
Methodological Strengths
- Prospective cohort with standardized 12-zone LUS within 6 hours of birth
- Robust statistical approach including ROC/DeLong tests, multivariable Cox models, and bootstrap internal validation
Limitations
- Single-center design limits generalizability; external validation is pending
- Observational prognostic study; does not test management changes based on the score
Future Directions: External validation in multicenter cohorts and impact analysis to determine whether score-guided management improves outcomes.
BACKGROUND: Respiratory distress syndrome (RDS) remains a major cause of morbidity in very preterm infants. Lung ultrasound score (LUS) provides a bedside assessment of lung aeration and has demonstrated utility for early respiratory decision-making, but its prognostic performance for long-term outcomes is only moderate. Procalcitonin (PCT) measured in umbilical cord blood may reflect perinatal inflammatory exposure and risk of infection-related complications. METHODS: We conducted a single-center prospective cohort study enrolling infants born at 24 + 0-33 + 6 weeks' gestation who were admitted to the NICU within 6 h of birth and were clinically diagnosed with RDS. Within 6 h after delivery, a standardized 12-zone LUS and umbilical cord-blood PCT were obtained. The primary endpoint was a composite of bronchopulmonary dysplasia, severe intraventricular hemorrhage, necrotizing enterocolitis, culture-proven sepsis occurring after 72 h of age, or all-cause death within 12 months' corrected age. Discrimination was evaluated using ROC analysis and DeLong tests. Time-to-first-event associations were examined using multivariable Cox regression. Internal validation used bootstrap optimism correction. RESULTS: Among 290 infants, 110 (37.9%) reached the composite endpoint (event-free proportion 62.1%). LUS alone achieved an AUC of 0.76 (95% CI 0.70-0.82), and PCT alone an AUC of 0.78 (0.72-0.84). A logistic model combining LUS and log-transformed PCT improved discrimination to an AUC of 0.87 (0.83-0.92), outperforming each single marker (paired DeLong CONCLUSIONS: In preterm infants with RDS, early integration of 12-zone LUS and cord-blood PCT improves prediction of 12-month major morbidity or death compared with either marker alone. This bedside approach may support early risk stratification. External validation and impact studies are needed before score-guided management is recommended.
3. Facilitating Macrophage Uptake of DNA Nanostructures for Integrated Imaging and Therapy of Acute Respiratory Distress Syndrome.
PolyG modification of tetrahedral DNA markedly enhances macrophage internalization, enabling high-sensitivity imaging of miR-155 and multifunctional anti-inflammatory treatment in ARDS models. The platform integrates diagnostic sensing and therapy within macrophages, addressing a key barrier to intracellular delivery.
Impact: Introduces a macrophage-targeted DNA nanostructure that unifies intracellular imaging of a proinflammatory miRNA with anti-inflammatory therapy, opening a theranostic avenue for ARDS.
Clinical Implications: If validated in vivo and clinically, macrophage-targeted DNA nanostructures could enable bedside monitoring of inflammatory signaling (e.g., miR-155) and deliver targeted anti-inflammatory therapy in ARDS.
Key Findings
- PolyG modification significantly promotes macrophage internalization of tetrahedral DNA nanostructures.
- High-sensitivity intracellular imaging of miR-155 in macrophages was achieved using multifunctional TETs.
- The platform delivered anti-inflammatory treatment for ARDS, integrating imaging and therapy.
Methodological Strengths
- Rational nanostructure engineering (polyG modification) to overcome intracellular delivery barriers
- Theranostic validation combining nucleic acid sensing and anti-inflammatory function in macrophages
Limitations
- Preclinical scope; in vivo efficacy, safety, and biodistribution require thorough evaluation
- Manufacturability and scalability of multifunctional TETs for clinical translation remain to be established
Future Directions: Advance to in vivo ARDS models for efficacy/toxicity, optimize targeting and payload, and assess clinical feasibility for macrophage-guided theranostics.
Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory disorder. While supportive care has improved, mortality remains high. So better diagnostics and targeted therapies are necessary. Tetrahedral DNA (TET) has been widely studied and applied in fields such as biosensors, drug delivery, and bioimaging. However, the cellular internalization capacity of traditional TET remains limited, which makes it challenging to apply TET for imaging or drug delivery inside cells. Here, we found that polyG modified on TET can promote it to be internalized into macrophages significantly. Based on this, we have achieved high-sensitivity imaging of miR-155 in macrophages and anti-inflammatory treatment for ARDS through synthesizing multifunctional TETs. When imaging miR-155, we created a multifunctional tetrahedral DNA (TET-H